Data Sheet (Cat.No.T13257)

TargetMol

Upamostat

Chemical Properties



CAS No. : 590368-25-5

Formula: C32H47N5O6S

Molecular Weight: 629.81

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.
Targets(IC50)	PAI-1,Serine Protease,Serine/threonin kinase
In vitro	Upamostat is an inhibitor of urokinase plasminogen activator (uPA). Upamostat is the oral prodrug of the active metabolite WX-UK1, a novel inhibitor of uPA [1]. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, and plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1 [2].

Solubility Information

Solubility	DMSO: 250 mg/mL (396.95 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 3.3 mg/mL (5.24 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5878 mL	7.9389 mL	15.8778 mL
5 mM	0.3176 mL	1.5878 mL	3.1756 mL
10 mM	0.1588 mL	0.7939 mL	1.5878 mL
50 mM	0.0318 mL	0.1588 mL	0.3176 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.

Froriep D, et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4.

Park C, et al. HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2018 Feb 20;150:39-42.